Iain McGill is the founder of Quell Therapeutics. Quell Therapeutics has raised $344M in total funding. Latest round: Series B.
Iain McGill is the Co-founder and CEO of Quell Therapeutics, a biotechnology company developing engineered T-regulatory (Treg) cell therapies for autoimmune diseases and organ transplant rejection. He announced the company's Series A expansion to approximately $84 million, which became the largest Series A in the Treg cell therapy space. McGill leads Quell's clinical pipeline, which includes one active clinical trial as of recent reports.
Full founder directory · Investor directory · Company funding database · Fundraising library